News

The patent (USP 7,678,824) entitled ‘Methods for Treatment with Bucindolol Based on Genetic Targeting,’ provides protection in the US for this approach to treat patients with heart failure,

Bionomics has already commenced Phase II testing of the anti-cancer properties of BNC105 in renal cancer in the US. The commencement of these two Phase II trials follows

The complaint was regarding patent infringement under US patent No 7,682,612 based on GSK’s manufacture, marketing and sale of Arzerra in the US for the treatment of fludarabine

ALX-0171 is a Nanobody product which binds to RSV and neutralizes the virus. The Nanobody is expected to be administered via lungs and based on the in-vivo data

The study, called Surpass, is expected to enroll 1,800 patients in 27 countries and provide direct comparative data of different treatment options for RRMS patients who experience breakthrough

Oramed Pharma said that the Phase 2b trial is a randomised, double-blind, placebo-controlled, multi-centered study, that primary evaluated the safety, and tolerability of Oramed’s oral insulin delivery technology.

The delivery system can be used for pharmaceutical, biopharmaceutical, medical foods, and nutraceutical products. In addition to the existing New Zealand patent, this patent covers the company’s multi-phase,

The Collaborative Research Initiative will be a strategic expansion of the company’s ‘Project Boveri: Find the Cure,’ adding the ability to monitor hourly chromosome aneuploidy progression. ChromoCure’s technology

Salix Pharma said that FDA approval of Xifaxan 550mg tablets was based on a 299 subject, double-blind, placebo-controlled, multinational, Phase 3 clinical trial. Trial results demonstrated a positive